Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -9 of 9
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
18 and over
Pharmaceutical / Industry
20040135
NCT00089661
2.
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
18 and over
Pharmaceutical / Industry
20040138
HALT, NCT00089674
3.
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
20050147
NCT00286091
4.
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
20050136
NCT00321464
5.
Double-Blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
20050244
NCT00330759
6.
AMG 162 in Bisphosphonate Naive Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
20040113
NCT00091832
Last Modified:
7/10/2007
 
First Published:
6/9/2006
7.
Phase II Study of Denosumab in Patients With Relapsed or Plateau-Phase Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
FHCRC-2082.00
AMGEN-20050134, NCT00259740
8.
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
20050134
NCT00259740
9.
Safety and Efficacy Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
20040215
NCT00396279
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute